<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085462</url>
  </required_header>
  <id_info>
    <org_study_id>040181</org_study_id>
    <secondary_id>04-C-0181</secondary_id>
    <secondary_id>NCI-6470</secondary_id>
    <secondary_id>CDR0000370798</secondary_id>
    <nct_id>NCT00085462</nct_id>
    <nct_alias>NCT00082264</nct_alias>
  </id_info>
  <brief_title>Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting a gene that has been created in the laboratory into a person's white&#xD;
      blood cells may make the body build an immune response to kill tumor cells. Interleukin-2 may&#xD;
      stimulate a person's white blood cells to kill tumor cells. Vaccines may make the body build&#xD;
      an immune response to kill tumor cells. Combining gene-modified white blood cell infusions&#xD;
      with interleukin-2 and vaccine therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying how well giving gene-modified white blood cells when&#xD;
      given together with interleukin-2 and vaccine therapy works in treating patients with&#xD;
      metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine, preliminarily, any clinical tumor regression in lymphodepleted patients with&#xD;
           metastatic melanoma treated with fowlpox gp100 antigen immunization and antitumor&#xD;
           antigen T-cell receptor (TCR)-engineered tumor infiltrating lymphocytes or CD8+&#xD;
           autologous peripheral blood lymphocytes followed by interleukin-2.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the in vivo survival of TCR gene-engineered cells in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to their ability to produce tumor-infiltrating&#xD;
      lymphocytes (TIL) (yes vs no).&#xD;
&#xD;
      Patients receive lymphodepleting chemotherapy comprising cyclophosphamide IV over 1 hour on&#xD;
      days -7 and -6 and fludarabine IV over 30 minutes on days -5 to -1.&#xD;
&#xD;
        -  Stratum 1 (TIL): Patients receive TIL retrovirally transduced with gp100 antigen TCR&#xD;
           gene IV over 20-30 minutes on day 0*.&#xD;
&#xD;
        -  Stratum 2 (CD8+peripheral blood lymphocytes [PBL]): Patients receive CD8+PBL&#xD;
           retrovirally transduced with gp100 antigen TCR gene IV over 20-30 minutes on day 0*.&#xD;
&#xD;
      NOTE: *Day 0 is 1-4 days after the last dose of fludarabine.&#xD;
&#xD;
      Patients in both strata also receive fowlpox-gp100 vaccine (before TIL/PBL infusion) IV over&#xD;
      1-2 minutes on days 0 and 28 and high-dose interleukin-2 (IL-2) IV over 15 minutes every 8&#xD;
      hours on days 0-4 and days 28-32. Patients also receive G-CSF SC once daily beginning on day&#xD;
      0 and continuing until blood counts recover.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity. Beginning&#xD;
      6-8 weeks after the last dose of vaccine and high-dose IL-2, patients with stable or&#xD;
      responding disease may receive 1 retreatment course.&#xD;
&#xD;
      Responding patients are followed at 1, 3, 6, and 12 months and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 61 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100-fowlpox vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of melanoma&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Refractory to standard therapy, including high-dose interleukin-2 therapy&#xD;
&#xD;
          -  HLA-A*0201 positive&#xD;
&#xD;
          -  Progressive disease during prior immunization to melanoma antigens OR prior treatment&#xD;
             with anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010)&#xD;
             cellular therapy with or without myeloablation allowed provided toxicity resolved to ≤&#xD;
             grade 2 (except vitiligo) AND patient does not require systemic steroids&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL&#xD;
&#xD;
          -  Lymphocyte count &gt; 500/mm^3&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL (3.0 mg/dL in patients with Gilbert's syndrome)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative (unless antigen negative)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ 45% by cardiac stress test&#xD;
&#xD;
               -  No LVEF &lt; 45% in patients ≥ 50 years of age&#xD;
&#xD;
          -  No myocardial infarction&#xD;
&#xD;
          -  No cardiac arrhythmias&#xD;
&#xD;
          -  No symptomatic cardiac ischemia&#xD;
&#xD;
          -  No prior EKG abnormalities&#xD;
&#xD;
          -  No other major cardiovascular illness&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 ≥ 60% of predicted AND no obstructive or restrictive pulmonary disease&#xD;
&#xD;
          -  No symptoms of respiratory dysfunction&#xD;
&#xD;
          -  No other major respiratory illness&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Epstein-Barr virus positive&#xD;
&#xD;
          -  No active systemic infections (including opportunistic infections)&#xD;
&#xD;
          -  No form of primary (e.g., autoimmune colitis or Crohn's disease) or secondary&#xD;
             immunodeficiency (due to chemotherapy or radiotherapy)&#xD;
&#xD;
          -  No prior severe immediate hypersensitivity reaction to any of the study agents&#xD;
             including eggs&#xD;
&#xD;
          -  No other major illness of the immune system&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 month after study&#xD;
             participation&#xD;
&#xD;
          -  Willing to complete a durable power of attorney (DPA)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 6 weeks since prior MDX-010&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since other prior systemic therapy and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

